



January 4, 2021

FILED BY SEDAR

British Columbia Securities Commission (*Principal Regulator*)
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Ontario Securities Commission
Financial and Consumer Services Commission, New Brunswick
Superintendent of Securities, Department of Justice and Public Safety, Prince Edward Island
Nova Scotia Securities Commission
Superintendent of Securities, Newfoundland and Labrador

Dear Sirs / Mesdames:

Re: HAVN Life Sciences Inc.
Final Short Form Prospectus dated January 4, 2021 (the "Prospectus")
SEDAR Project Number 03151640

We refer to the Prospectus of the HAVN Life Sciences Inc. (the "**Corporation**") qualifying the distribution of units comprised of one common share of the Corporation and one common share purchase warrant at a price of \$1.07 per Unit.

We, as counsel for the Corporation, hereby consent to the use of and reference to our firm opinions under the headings "*Eligibility for Investment*" and "*Certain Canadian Federal Income Tax Considerations*" and to the reference to our firm name on page ii of the Prospectus and under the heading "*Interest of Experts*".

We confirm that we have read the Prospectus and that we have no reason to believe that there are any misrepresentations in the information contained therein that is derived from our opinions referred to above or that is within our knowledge as a result of the services we performed in connection with such opinions.

Yours truly,

"Cassels Brock & Blackwell LLP"